

Catalog # 10-3050

Nelfinavir mesylate

CAS# 159989-65-8

(3*S*,4a*S*,8a*S*)-*N*-(1,1-Dimethylethyl)decahydro-2-[(2*R*,3*R*)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate

> AG-1343 Lot # X109336



Nelfinavir is a clinically useful anti-HIV agent acting via inhibition of HIV-1 protease (K_i=2 nM).¹ It also displays efficacy in cancer, malaria, tuberculosis and SARS.² Displays broad spectrum anticancer activity and induces endoplasmic reticulum stress, autophagy and apoptosis *in vitro* and *in vivo*.³ Inhibits the growth of HER2-positive breast cancer cells via inhibition of HSP90 through a novel mechanism.⁴

- Olmo et al. (2006), A review of nelfinavir for the treatment of HIV infection; Expert Opin. Drug Metab. Toxicol., 2
 285
- 2) Bruning et al. (2010), New prospects for nelfinavir in non-HIV-related diseases; Curr. Mol. Pharmacol., 3 91
- 3) Gills et al. (2007), Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo; Clin. Cancer Res, **13** 5183
- *4)* Shim *et al.* (2012), Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir, J. Natl. Cancer Inst,, **104** 1576

PHYSICAL DATA

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.